

WHAT IS CLAIMED IS:

1. Use of at least one PD-1 and/or PD-L1 antibody in the manufacture of a medicament for treating cancer in a patient, wherein the medicament is to be used in a treatment cycle wherein:
 - (a) the patient is to be administered with fractionated radiation therapy,
wherein the fractionated radiation therapy comprises 5 radiation therapy fractions, and a dose of each radiation therapy fraction is about 2 Gy,
wherein the total dose of fractionated radiation therapy is about 10 Gy or lower;
and
 - (b) the medicament is to be administered on the same day as a radiation therapy fraction or up to and including 4 days later, and wherein the medicament is to be administered 3 times a week and,
wherein the treatment cycle is to be performed every other week.
2. The use according to claim 1, wherein the radiation therapy fractions are to be administered on sequential days.
3. The use according to claim 2, wherein the radiation therapy fractions are to be administered on day 1, day 2, day 3, day 4, and day 5.
4. The use according to claim 1, wherein the medicament is to be administered on day 1 of the fractionated radiation therapy.
5. The use according to claim 1, wherein the medicament is to be administered on day 5 of the fractionated radiation therapy.
6. The use according to claim 1, wherein the anti-PD-1 and/or PD-L1 antibody is durvalumab (MEDI4736).
7. The use according to claim 1, wherein the anti-PD-1 and/or anti-PD-L1 antibody is pembrolizumab, nivolumab (BMS-936558), or atezolizumab (MPDL3280A).
8. The use according to claim 1, wherein the cancer is melanoma, colorectal cancer or breast cancer.
9. The use according to claim 1, wherein more than one treatment cycle is to be performed.

10. The use according to claim 9, wherein from 2-8 treatment cycles are to be performed.